Impression Healthcare commences obstructive sleep apnoea clinical trial

Impression has registered a phase 2a randomised controlled clinical trial to investigate the effect of IHL-42X on obstructive sleep apnoea versus a placebo.

Following last week’s deal that saw Impression Healthcare (ASX: IHL) secure the cannabinoid materials it needs to conduct a series of clinical trials, the cannabis company has announced that it has successfully registered its second clinical trial.

Earlier today, Impression confirmed it will investigate the efficacy of its unique IHL-42X medicinal cannabis formulation on obstructive sleep apnoea with secondary outcome measures focused on sleep quality and patient mood.

The IHL-42X cannabinoid formulation for the clinical trial was prepared in full accordance with Australian Good Manufacturing

... read more at: https://smallcaps.com.au/impression-healthcare-commences-obstructive-sleep-apnoea-clinical-trial/

by

Leave a Reply